{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/lyme-disease/prescribing-information/azithromycin/","result":{"pageContext":{"chapter":{"id":"245cb0af-f052-5aa2-8912-6e553063438e","slug":"azithromycin","fullItemName":"Azithromycin","depth":2,"htmlHeader":"<!-- begin field 88709f96-ab95-48c1-9697-e0c29b0abfb5 --><h2>Azithromycin</h2><!-- end field 88709f96-ab95-48c1-9697-e0c29b0abfb5 -->","summary":"","htmlStringContent":"<!-- begin item cd659d98-b980-4e1d-92c7-e9ef4a2abedf --><!-- end item cd659d98-b980-4e1d-92c7-e9ef4a2abedf -->","topic":{"id":"56ba86e1-b79d-5c00-948b-65c581b69f79","topicId":"7aa291ec-f53e-44b9-8a66-e9b4ee6a577f","topicName":"Lyme disease","slug":"lyme-disease","lastRevised":"Last revised in August 2019","chapters":[{"id":"5995c194-77ea-5203-83e7-86b64985db74","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cc168196-a2da-5a8f-873c-fb75c4c3960f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a8622b23-7f1f-543b-b5ba-e9f4c9547c1c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4c25a599-a26d-5702-b9f6-43dff73c83c8","slug":"changes","fullItemName":"Changes"},{"id":"29379f04-710e-5ce7-ba07-ea9a1e178ac7","slug":"update","fullItemName":"Update"}]},{"id":"bc55cfd2-4253-598a-8be1-54061ce22b6a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"49a7229f-6129-58a8-9b6e-7471ccde1b15","slug":"goals","fullItemName":"Goals"},{"id":"ca83767e-8bdd-5ab2-b78a-c8577ab6da08","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"928ab402-0b5e-53b7-96d3-a64275903911","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d5230b0a-b405-5725-9a8a-95f4a63239e1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a9b48f27-60ba-54c9-9deb-e1ce41732fc9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5cc0f690-6775-5131-a1fc-75d9efa0b535","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8bbfecb1-6cb7-511b-9697-7915788a4bff","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"1c94f9ce-3656-59d3-86ed-d515d113270a","slug":"definition","fullItemName":"Definition"},{"id":"1a4679d0-b6d3-5b97-917c-5d08de1be33b","slug":"causes","fullItemName":"Causes"},{"id":"6e585a22-8dfe-578a-99a9-1be143896b7f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e1ded21e-6325-5c18-ae0a-6b540cd28c19","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"126215ba-45c3-5bbf-ae98-2fff7bb1ed89","slug":"prognosis","fullItemName":"Prognosis"},{"id":"5240144c-4a60-5d30-ab1e-63d4f2995a2f","slug":"complications","fullItemName":"Complications"},{"id":"a5092448-11ae-5b17-8a6b-8b6f6d5b80cf","slug":"other-tick-borne-diseases","fullItemName":"Other tick-borne diseases"}]},{"id":"d2ae2f81-2546-5ff8-8002-577ff4741f57","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0cf6a4b7-b848-5424-b311-ae2e70bf1cf4","slug":"when-to-suspect-lyme-disease","fullItemName":"When to suspect Lyme disease"},{"id":"868a26b1-1742-50d5-8576-14ab327a0c64","slug":"differential-diagnosis-erythema-migrans","fullItemName":"Differential diagnosis (erythema migrans)"}]},{"id":"1a2edd0e-8cc2-5cce-aa6f-5519b5f40775","fullItemName":"Management","slug":"management","subChapters":[{"id":"35e8dbb5-da7f-5fd3-9ff3-b9926f24ed6e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"8d378757-a1b8-5c8c-95b4-d1428557dcb3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"10094473-f953-57de-8453-10fc5a4709a2","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"714c78fe-f533-5abf-8ab9-28bdb2658044","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"245cb0af-f052-5aa2-8912-6e553063438e","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"98b0aa55-4436-555a-bfde-05ef12f03083","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0edcddd4-56b7-5124-b56a-14f7a38f3fd5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d42dec32-1352-5fb5-8d7d-c3591bae0448","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"254e7467-a025-51bb-849c-803edae01e3b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"659f6620-1672-5b1d-bf3e-891ce69b4ff1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fdc13e77-5b9e-59a9-b651-15a5e1b1f333","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ccedf4e2-7c6a-5251-abee-5f5f14e5ed39","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a2095079-fcfd-5a3f-85e9-d631c57dd891","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"8d378757-a1b8-5c8c-95b4-d1428557dcb3","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"ae8de661-8544-55c5-a1a4-cc9f3c496a5b","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field e939f20e-07dc-46fe-888a-1b16f4da0604 --><h3>Contraindications and cautions </h3><!-- end field e939f20e-07dc-46fe-888a-1b16f4da0604 -->","summary":"","htmlStringContent":"<!-- begin item bf616e31-70ab-4b3c-a0ee-2bc0a83e6fa6 --><!-- begin field aa7ef463-483b-4118-a685-9c3019d05b68 --><ul><li><strong>Do not prescribe azithromycin in people:</strong><ul><li>With severe hepatic impairment.</li></ul></li><li><strong>Prescribe azithromycin with caution in people:</strong><ul><li>Who may be predisposed to prolongation of the QT interval. For example, people with:<ul><li>Congenital or documented acquired QT prolongation.</li><li>Currently receiving treatment with other active substances known to prolong the QT interval such as antiarrhythmics of classes IA and III.</li><li>With electrolyte disturbance, particularly in cases of hypokalaemia and hypomagnesaemia.</li><li>With clinically relevant bradycardia, cardiac arrhythmia, or severe cardiac insufficiency, including Torsades de pointes.</li></ul></li><li>With mild to moderate hepatic impairment.</li><li>With severe renal impairment.</li><li>With myasthenia gravis — macrolides may aggravate symptoms.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">BNF 75, 2018</a>]</p><!-- end field aa7ef463-483b-4118-a685-9c3019d05b68 --><!-- end item bf616e31-70ab-4b3c-a0ee-2bc0a83e6fa6 -->","subChapters":[]},{"id":"cad3ee7a-941a-5659-94aa-d2a9736dbaff","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 5c87d8b7-a1c7-4b57-aac5-bad30dc46cea --><h3>Adverse effects </h3><!-- end field 5c87d8b7-a1c7-4b57-aac5-bad30dc46cea -->","summary":"","htmlStringContent":"<!-- begin item 59c71f8a-44ed-4fdb-bbe8-43c0763b8881 --><!-- begin field dc60dda6-10a0-4e16-b3f7-59254dc243b3 --><ul><li><strong>Gastrointestinal</strong> — diarrhoea (very common), vomiting, abdominal pain, nausea (common).<ul><li><strong>Rarely:</strong> pancreatitis, pseudomembranous colitis (for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Nervous system</strong> — headache (common), dizziness, somnolence, dysgeusia, paraesthesia (uncommon).<ul><li><strong>Rarely:</strong> convulsions, hyperactivity, syncope, myasthenia gravis.</li></ul></li><li><strong>Psychiatric</strong> — nervousness, insomnia (uncommon).<ul><li><strong>Rarely or very rarely:</strong>  agitation, aggression, anxiety, delirium, hallucination.</li></ul></li><li><strong>Skin</strong> <strong>and subcutaneous tissue</strong> — rash, pruritus, urticaria, dermatitis (uncommon).<ul><li><strong>Rarely, or very rarely:</strong> Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens Johnson syndrome, toxic epidermal necrolysis, erythema multiforme.</li></ul></li><li><strong>Other adverse effects reported rarely, or very rarely, include:</strong> <ul><li>Anaphylaxis.</li><li>Arrhythmias.</li><li>Arthralgia.</li><li>Deafness.</li><li>Hepatitis, cholestatic jaundice.</li><li>Pancreatitis. </li><li>QT interval prolongation.</li></ul></li><li><strong>Jarisch–Herxheimer reaction </strong>— this has been observed in about 15% of people with Lyme disease. It is a systemic reaction thought to be caused by the release of cytokines when antibiotics kill large numbers of bacteria. Symptoms include a worsening of fever, chills, muscle pains and headache. It may be mistaken for an allergic reaction and the person may stop their antibiotics. The reaction can start between 1–12 hours after antibiotics are started, but can also occur later and can last for a few hours or 1–2 days. The reaction is self-limiting and usually resolves within 24–48 hours. Provided the symptoms are not severe and there is no evidence of an allergic reaction (such as urticaria), the person can be advised to continue the antibiotic.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">Dubrey et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">NICE, 2018a</a>]</p><!-- end field dc60dda6-10a0-4e16-b3f7-59254dc243b3 --><!-- end item 59c71f8a-44ed-4fdb-bbe8-43c0763b8881 -->","subChapters":[]},{"id":"da87ecf6-643a-5d00-9148-7db9b4c44af1","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field d9c526f9-3a7a-4e76-bc21-a3d8034cfb6d --><h3>Drug interactions</h3><!-- end field d9c526f9-3a7a-4e76-bc21-a3d8034cfb6d -->","summary":"","htmlStringContent":"<!-- begin item fed6e765-4ede-4393-83a1-7a54a82905f5 --><!-- begin field 313fb16f-5781-49c7-a7cb-d3ac2d6e09d7 --><ul><li><strong>Antacids</strong> — plasma concentrations of azithromycin may be reduced. Simultaneous administration should be avoided — azithromycin should be taken at least 2 hours before, or 1 hour after antacids.</li><li><strong>Ciclosporin</strong> — azithromycin can affect clearance of ciclosporin. If co-administration of these drugs is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.</li><li><strong>Colchicine</strong> — azithromycin slightly increases the levels of colchicine. Monitor for signs of colchicine toxicity (for example, nausea, vomiting, diarrhoea, myopathy, and pancytopenia).</li><li><strong>Digoxin</strong> — macrolides increase digoxin levels. However, the risk of toxicity may be lower with azithromycin than with clarithromycin. Monitor and reduce the digoxin dose if required.</li><li><strong>Edoxaban </strong>— levels may be increased by azithromycin. Dose adjustment of edoxaban may be required.</li><li><strong>Ergot derivatives</strong> — there is a theoretical possibility of ergot toxicity if taken concomitantly with azithromycin. The manufacturer of azithromycin recommends avoiding.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of azithromycin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Rifabutin</strong> — azithromycin increases the risk of neutropenia when given with rifabutin. Monitor closely.</li><li><strong>Statins</strong> — there is a possible increased risk of myopathy.<ul><li>Advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Warfarin</strong> — occasionally and unpredictably, the effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Drugs that prolong the QT interval</strong> (such as amiodarone, or sotalol) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.<ul><li>Use an alternative antibiotic and/or seek advice from a microbiologist.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">BNF 75, 2018</a>]</p><!-- end field 313fb16f-5781-49c7-a7cb-d3ac2d6e09d7 --><!-- end item fed6e765-4ede-4393-83a1-7a54a82905f5 -->","subChapters":[]},{"id":"e2871da1-d0c2-5e2f-9532-5c84bc015b96","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 08c84f1b-f3e8-4599-a831-60ccad35871a --><h3>Pregnancy and breastfeeding</h3><!-- end field 08c84f1b-f3e8-4599-a831-60ccad35871a -->","summary":"","htmlStringContent":"<!-- begin item 8683417a-767f-4293-8a06-90a66b574d82 --><!-- begin field 4553879b-5712-4043-8c4d-0ed4877ca0fd --><h4>Pregnancy</h4><ul><li>There is limited data available on the use of azithromycin in women who are pregnant. Avoid use unless a suitable alternative is not available.</li></ul><h4>Breastfeeding</h4><ul><li>Present in breastmilk — avoid use unless a suitable alternative is not available.</li><li>If used in women who are breastfeeding, the manufacturer recommends discarding the milk during treatment and for two days after discontinuation of treatment. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">BNF 75, 2018</a>]</p><!-- end field 4553879b-5712-4043-8c4d-0ed4877ca0fd --><!-- end item 8683417a-767f-4293-8a06-90a66b574d82 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}